GSK Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by GSK Plc, dated November 3, 2025, serves as a notification to the market regarding the company's total voting rights and capital structure. The report is submitted in conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R. The data reflects the company's status as of October 31, 2025.
Key Financial Metrics
The filing does not provide financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document is strictly a capital structure notification.
Material Changes
The filing does not contain comparative data against prior periods or discuss material changes in financial performance. It solely reports the current share capital composition.
Guidance, Outlook, and Risks
The document contains no management commentary, future guidance, risk factors, contingencies, or unusual items. Its sole purpose is to provide the denominator for shareholder interest calculations under FCA rules.
Key Facts for Investors
- Issued Share Capital: As of October 31, 2025, GSK Plc had 4,315,423,599 Ordinary Shares of 31.25 pence each.
- Treasury Shares: 254,768,344 Ordinary Shares were held in Treasury.
- Total Voting Rights: The total number of voting rights is 4,060,655,255.
- Shareholder Notification: Shareholders should use the total voting rights figure (4,060,655,255) as the denominator to determine if they must notify the company of their interest or changes thereto.
- Contact: Notifications regarding share interests should be sent to company.secretary@gsk.com.